Salarius Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Salarius Pharmaceuticals has a total shareholder equity of $3.6M and total debt of $116.9K, which brings its debt-to-equity ratio to 3.2%. Its total assets and total liabilities are $4.9M and $1.2M respectively.
Key information
3.2%
Debt to equity ratio
US$116.86k
Debt
| Interest coverage ratio | n/a |
| Cash | US$4.37m |
| Equity | US$3.65m |
| Total liabilities | US$1.23m |
| Total assets | US$4.88m |
Recent financial health updates
Recent updates
Salarius pharmaceuticals announces 1-for-25 reverse stock split
Oct 14Salarius adds 12% after updates on clinical programs and financials
Sep 13Salarius Pharma adds two Mayo Clinic sites to phase 1/2 trial of Seclidemstat as treatment for cancers
Aug 22Salarius Pharmaceuticals GAAP EPS of -$0.09 beats by $0.01
Aug 08Salarius Pharmaceuticals and VolitionRx enter into R&D collaboration agreement
Aug 02Salarius Pharma reports new seclidemstat results in Ewing sarcoma and other solid tumors at ASCO21
Jun 07Salarius Pharmaceuticals (SLRX) Investor Presentation - Slideshow
May 27Salarius Pharmaceuticals (NASDAQ:SLRX) Shareholders Have Enjoyed An Impressive 155% Share Price Gain
Feb 09
Salarius Pharmaceuticals receives second installment of $1.7M in payments
Jan 13Salarius Pharma raises $3.5M via warrant exercise
Dec 11Salarius Pharmaceuticals EPS in-line, beats on revenue
Nov 11Financial Position Analysis
Short Term Liabilities: SLRX's short term assets ($4.8M) exceed its short term liabilities ($1.2M).
Long Term Liabilities: SLRX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: SLRX has more cash than its total debt.
Reducing Debt: SLRX's debt to equity ratio has increased from 0% to 3.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SLRX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SLRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 27.6% each year